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Abstract
Background: With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for
the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far,
volumetric brain changes have been proposed as clinical endpoints in the literature, but cognitive scores are still lacking.
This study followed disease progression predominantly in language-based performance within 1 year and defined a PPA
sum score which can be used in therapeutic interventions.
Methods:We assessed 28 patients with nonfluent variant PPA, 17 with semantic variant PPA, 13 with logopenic variant PPA,
and 28 healthy controls in detail for 1 year. The most informative neuropsychological assessments were combined to a sum
score, and associations between brain atrophy were investigated followed by a sample size calculation for clinical trials.
Results: Significant absolute changes up to 20% in cognitive tests were found after 1 year. Semantic and phonemic word
fluency, Boston Naming Test, Digit Span, Token Test, AAT Written language, and Cookie Test were identified as the best
markers for disease progression. These tasks provide the basis of a new PPA sum score. Assuming a therapeutic effect of
50% reduction in cognitive decline for sample size calculations, a number of 56 cases is needed to find a significant
treatment effect. Correlations between cognitive decline and atrophy showed a correlation up to r = 0.7 between the sum
score and frontal structures, namely the superior and inferior frontal gyrus, as well as with left-sided subcortical structures.
Conclusion: Our findings support the high performance of the proposed sum score in the follow-up of PPA and
recommend it as an outcome measure in intervention studies.
Keywords: Frontotemporal dementia, Cognitive neuropsychology in dementia, Assessment of cognitive disorders/
dementia, Volumetric MRI, Aphasia
Background
Primary progressive aphasia (PPA) comprises a group of
neurodegenerative disorders in which language problems
are the principal cause of impaired daily living activities,
whereas other neurobehavioral or cognitive deficits are
rare during the initial stages of the illness [1]. PPA can be
classified into three clinical subtypes [2]. The nonfluent/
agrammatic variant (nfvPPA) presents with agrammatism
in speech production and/or apraxia of speech with
additional impaired comprehension of syntactically com-
plex sentences, while object knowledge and single-word
comprehension are spared [2]. Patients with the semantic
variant (svPPA) have progressive deficits in comprehend-
ing single words as a widespread semantic memory deficit,
often combined with impaired object knowledge and
surface dyslexia or dysgraphia [2]. The logopenic variant
(lvPPA) is specified by difficulties finding words and
impaired sentence repetition [2, 3]. Typically, nfvPPA and
svPPA are syndromes with underlying frontotemporal
lobar degeneration (FTLD) pathology, i.e., nfvPPA is
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frequently linked to FTLD-tau, whereas svPPA is associ-
ated with FTLD-TDP [4]. In contrast, lvPPA often has an
underlying Alzheimer’s disease pathology [5].
Several studies provide an initial insight into the pro-
gression of PPA [6–9]. Knopman et al. [8] measured
whole brain and ventricular volume changes within
1 year in FTLD patients, including 17 nfvPPA, 16 svPPA,
and 9 lvPPA, amongst others. A slightly higher whole
brain atrophy rate was found in lvPPA than in nfvPPA
and svPPA. Rogalski et al. [9] examined the longitudinal
course of PPA over a 2-year period in 10 nfvPPA, 8
svPPA, and 8 lvPPA patients. They concluded that
analyzing a focal cortical language network is a more
sensitive clinical outcome measure than whole brain or
ventricular volume measures. However, none of these
studies provided a clinical tool that can be used for
comprehensive language assessment and for sample size
calculation of a clinical trial. This is, however, prerequis-
ite for any upcoming trials, e.g., using tau protein
immunization strategies [10].
The aim of this study was to follow disease progres-
sion predominantly using language-based performance
in detail and to define a practicable and effective PPA
sum score which can be used in planning clinical trials.
Additionally, brain atrophy was investigated in prede-
fined regions as a first exploratory validation step of this
sum score.
Methods
Subjects
We report 1-year follow-up data of 58 PPA patients, in-
cluding 28 nfvPPA, 17 svPPA, and 13 lvPPA, and 28
neurologically healthy controls. All patients met the clin-
ical criteria suggested by Gorno-Tempini et al. [2], where-
upon the additional imaging supportive criteria applied to
48% of nfvPPA, 93% of svPPA, and 66.7% of lvPPA
patients. None of the 58 patients showed a known
mutation in MAPT, GRN, PSEN1, or C9orf72. On-site
monitoring was conducted for all participants. Patients
were recruited from 10 academic centers across Germany:
Bonn, Erlangen, Göttingen, Hamburg-Eppendorf, Homburg/
Saar, Leipzig, Munich, Rostock, Ulm, and Würzburg. The
study was approved by the local Ethics Committees (pro-
posal number at the central study center at University of
Ulm, 39/11, 8 March 2011), and written informed consent
was obtained from each patient, participant, caregiver, or
legal representative.
Neuropsychological assessment
Patients underwent an extensive neuropsychological
assessment covering a broad range of cognitive domains.
The language investigations included naming ability
(Boston Naming Test, 15-item short version from the
Consortium to Establish a Registry for Alzheimer's
Disease (CERAD)-plus battery [11]), word and sentence
comprehension (Token Test [12]), reading and writing abil-
ities (written language-subtest of the German Aachener
Aphasie Test (AAT) [13]), semantic knowledge and word
repetition (Repeat and Point Test [14]), phonemic and
semantic word fluency (“s-words” and category “animals”
[15]), and spontaneous speech production (“Cookie Theft
picture” [16]). The rating for the latter was defined by
mentioning 20 predefined items of the picture.
Episodic memory, visuo-spatial abilities, information
processing speed, and cognitive flexibility were measured
within the CERAD-plus battery. Executive functions such
as short-term and working memory capacity (Digit and
Block Span [17]), figural fluency [18], interference reso-
lution (standard Stroop Test, adapted from the European
Huntington’s Disease Network), and cognitive estimation
abilities [19] were included in the assessment protocol.
Clinical rating scales
The well-established Clinical Dementia Rating Scale
(CDR) [20] and the FTLD-specific rating scale (FTLD-
CDR) [21], the latter including two additive domains for
behavioral changes and language dysfunction, provide a
global score with the aim of staging the severity of
disease. Scoring was performed with the so-called “sum
of boxes score”, a summation of all domains.
Neurochemical markers
Cerebrospinal fluid (CSF) was taken by lumbar puncture
at baseline examination and analyzed for tau, phospho-
tau (ptau) and Abeta1–42 using commercially available
enzyme-linked immunosorbent assays (ELISAs) [22].
Imaging data acquisition
Patients underwent a 3-T magnetic resonance imaging
(MRI) scan at baseline examination and follow-up. We
analyzed 35 defined brain structures following a meta
analysis [23] which had been calculated by an atlas-based
volumetric (ABV) analysis beforehand. For a detailed
description of this procedure, see Steinacker et al. [24].
Data analysis
Statistical analyses were performed with IBM SPSS
Statistics for Windows, Version 21.0, and SAS 9.4. The
level of significance was set to p = 0.05. Kruskal-Wallis
tests, χ2 tests and post-hoc tests examined differences in
demographic variables, biomarker levels, and sum score
decline between the diagnostic groups. Cognitive change
and atrophy rate between baseline and follow-up were
analyzed by paired t tests, followed by a Bonferroni
correction for all volumetric structures and for each
domain-specific cluster (e.g., executive functions, mem-
ory, language). Spearman and partial correlations tested
for associations between the sum score and demographic
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variables, clinical rating scale, and atrophy rate; a
Bonferroni correction was applied if necessary. Sample
size calculations were based on the observed mean de-
cline in the sum score. The power was set to 80%, and
the alpha error level to 5% for the use of a unpaired t
test. A multiple imputation procedure (SAS 9.4 Proc MI
with fully conditional specification methods, FCS and re-
gression method, REG with ten consecutive imputation
calculations and an adjustment for variable age) cor-
rected for missing values for single neuropsychological
tests in the data matrix, ruling out systematic bias be-
forehand (e.g., influence of the study site on missing
values). Three cases were excluded from this procedure
because of a massive deterioration in cognitive perform-
ance. A correction of variance values was added [25].
Development of a sum score
The PPA sum score has been derived from those tests
that showed a strong decline within 1 year, covered a
broad range of relevant cognitive domains (e.g., naming,
fluency, word and sentence comprehension, reading and
writing ability, spontaneous speech production, verbal
short-term and working memory capacity), and had a
tolerable execution time.
We defined maximum attainable test scores for those
lacking an endpoint, which were additionally used to en-
able the presentation of absolute percentage changes in
the single assessments. In accordance with the mean ob-
served value in neurologically healthy controls (aver-
aging the scores for men and women as well as for
education [17, 26]), the maximum test score was set to
24 points for semantic fluency (category “animals”) and
to 12 points for phonemic fluency (“s-words”), respect-
ively. The Digit Span forward and backward were both
set to a maximum of 6 points. As higher values
represent better performance except for the Token Test,
the latter was reversed (zero errors result in 50 points,
whereas a maximum of 50 errors result in zero points).
For the “unbalanced” version of the sum score, we
simply calculated a summation of the eight test scores
attained, resulting in a maximum score of 223 points. As
the different attainable maximum test scores have a
range from 6 to 90 points and a simple summation of
the single scores therefore gives an unbalanced weight to
single tests, we decided to adjust every test score to a
maximum of 50 points via a simple multiplicative
transformation. The overall balanced sum score, with a
maximum attainable score of 400 points, is calculated as
follows:
Sum score = (verbal fluency animals × 2.083) + (Boston
Naming × 3.333) + (verbal fluency s-words × 4.167) + (Digit
Span forward × 8.333) + (Digit Span backward ×
8.333) + (AAT written language × 0.556) + Token Test
reversed + (Cookie Theft × 2.5).
Results
Demographics
Table 1 gives an overview of all demographic variables,
clinical rating scales, and biomarker values. Significant dif-
ferences between diagnostic groups concerning age of ini-
tial symptoms (p =0.022) and disease duration (p =0.040)
were found. Post-hoc tests revealed earlier symptom onset
(p =0.011) and longer disease duration (p =0.008) in
svPPA compared to nfvPPA.
Cognitive test results
Figure 1 shows the absolute percentage change rates in
cognitive assessment within 1 year for those tests selected
for the sum score. Detailed results of the paired t tests for
the whole assessment battery are listed in Additional file 1:
Table S1.
nfvPPA showed greater decline rates throughout the dif-
ferent tests than svPPA or lvPPA. Particularly worth
mentioning are performance changes in the Cookie Theft
(–22.2%, p < 0.001), the written language test (–18.4%,
p = 0.001), the repeat condition of the Repeat and
Point Test (–15.2%, p = 0.003), the Digit Span forward
(–20%, p < 0.001), and the semantic fluency (–12.3%,
p = 0002). svPPA also revealed a significant decline in
semantic fluency (–11.6%, p = 0.006) and in the Boston
Naming Test (–12.4%, p = 0.004). The phonemic fluency
showed a high decline rate but failed to reach significance
(–21.8%, p > 0.05). For lvPPA, the highest declines were
found in phonemic fluency (–16.7%), digit span backward
(–13.6%), wordlist saving (–15.3%), and the repeat condi-
tion of the Repeat and Point Test (–15.56%), but none of
them reached significance. Healthy controls did not show
any significant performance change. Regarding the FTLD-
CDR, only nfvPPA and svPPA revealed a significant
progression at 1 year. nfvPPA showed an increase in the
FTLD-CDR of 1.9 points (p = 0.001) and in the CDR of 1.3
points (p = 0.01). svPPA presented with an increase of 3.1
points in the FTLD-CDR (p = 0.012) and in the CDR of 2.4
points (p = 0.019).
Atrophy progression
nfvPPA showed a significant atrophy rate in the left-sided
superior frontal (–4.70%, p = 0.001), the left-sided superior
temporal (–4.49%, p < 0.001), and the right superior frontal
gyrus (–4.49%, p < 0.001). svPPA revealed a higher and
more bilateral atrophy rate, e.g., significant changes were
found in the insulae (left –6.57%, p = 0.001; right –5.91%,
p < 0.001), the left hippocampus (–9.04%, p = 0.001), the
left amygdala (–8.37%, p < 0.001), and in the left superior
frontal gyrus (–4.42%, p = 0.001). In lvPPA, significant
atrophy progression in the left middle temporal (–
4.15%, p = 0.001) and the left angular gyrus (–3.10%,
p < 0.001) was detected. For detailed results of all
paired t tests, see Additional file 2: Table S2.
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Fig. 1 Main cognitive test results within 1 year. Scores at baseline (v1) and follow-up after 1 year (v2) for the eight cognitive assessments that have
been included in the sum score. Boxes show the 25–75% percentile range with median, and whiskers indicate minimum and maximum. For an easier
comparison, we present absolute percentage scores that have been calculated by setting maximum sores as described in the Methods
section. *p < 0.05, significant changes within 1 year, calculated via paired t tests. lvPPA logopenic variant primary progressive aphasia, nfvPPA nonfluent
variant primary progressive aphasia, PPA primary progressive aphasia, svPPA semantic variant primary progressive aphasia
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The FTLDc-PPA sum score
Tests covering the different language domains were
chosen to be included in the PPA sum score. An import-
ant relevant factor, besides a significant decline, was seen
in the time required to perform the tests. We aimed for
a performance time between 30 and 40 min for the
whole sum score. As already mentioned in the Methods
section, we included tests covering word and sentence
comprehension, naming, reading and writing abilities,
verbal working memory capacity, semantic and phon-
emic retrieval, as well as spontaneous speech compe-
tence. The final sum score is presented either as raw
data (unbalanced version), meaning a simple summation
of test results (best 223 points), and as a weighted pres-
entation of test results (balanced version) in which all
speech domains have a similar representation (best 400
points, see Methods section).
Figure 2 shows the results observed for the balanced
score version, depending on the PPA diagnosis. There
was a highly significant decline in the sum scores within
1 year for all PPA subgroups with one exception in the
svPPA group for the unbalanced score. The decline rate
did not differ between the three subgroups and neuro-
logically healthy controls showed no significant change.
A significant correlation between education and both
sum score variants was found, with an association
between better performance and higher education level
(r = 0.33, p = 0.007 for the unbalanced score and r = 0.43,
p < 0.001 for the balanced version). All other demographic
variables, including age at baseline, disease duration, and
age at onset of disease, proved to be uncorrelated. Internal
consistency of both sum score variants was satisfying
(Cronbachs αbalanced score = 0.810, Cronbachs αunbalanced
score = 0.802).
Correlations between sum score and clinical rating
scale decline (controlling for education) showed no sig-
nificant association. However, correlating both values at
baseline status, again controlling for education, showed
noteworthy relationships (all p < 0.001) with runbalanced
score = –0.63 and rbalanced score = –0.64 for the CDR, and
runbalanced score = –0.62 and rbalanced score = –0.63 for the
FTLD-CDR.
Correlation analysis of FTLDc-PPA sum score and brain
atrophy
Correlating the decrease in cognitive and linguistic
performance and brain atrophy (both variables measured as
relative percentage change with education as a control vari-
able) showed a significant relationship between the left
cerebral cortex and the sum score (Fig. 3). We set aside
correlations for the subgroups due to small sample sizes.
The balanced sum score showed significant correlations
with the left frontal lobe (r = 0.647, p < 0.001), moreover
with the left superior frontal gyrus (r = 0.61, p = 0.001) and
with the left putamen (r = 0.593, p = 0.001). The unbalanced
version of the sum score showed nearly the same findings
for the left frontal lobe (r = 0.610, p = 0.001) and the left
Fig. 2 Balanced FTLDc PPA score results within 1 year. Balanced
FTLDc-PPA sum scores at baseline (v1) and at follow-up of 1 year
(v2). Boxes show the 25–75% percentile range with median, and
whiskers indicate minimum and maximum. *Significant changes
within 1 year, calculated via paired t tests are indicated by brackets
(healthy controls (HC): p= 0.780; nonfluent variant primary progressive
aphasia (nfvPPA): p= 0.002; semantic variant primary progressive aphasia
(svPPA): p= 0.016; logopenic variant primary progressive aphasia
(lvPPA): p= 0.001)
Fig. 3 Correlation between balanced sum score change and volumetric
change in left frontal lobe and left putamen. Both variables are measured
as relative percentage change. N= 28. lvPPA logopenic variant primary
progressive aphasia, nfvPPA nonfluent variant primary progressive aphasia,
svPPA semantic variant primary progressive aphasia
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putamen (r = 0.592, p = 0.001). After exclusion of one ex-
treme case from the calculation as an outlier, a nearly sig-
nificant correlation (after Bonferroni correction) between
the balanced sum score change and the left frontal lobe de-
crease (r = 0.576, p = 0.002) was revealed.
Sample size calculations for therapeutic trials
Assuming a minimum treatment effect of about 30%, a
sample size calculation was performed. Table 2 shows
the number of cases which are necessary to detect a
possible treatment effect in a placebo-controlled trial,
graded for different magnitudes of a treatment effect.
For example, assuming a treatment effect of 50% reduc-
tion for cognitive decline measured by the balanced sum
score, a cohort of 29 nfvPPA patients per group (placebo
and verum) is needed to prove a significant treatment
effect. Numbers for the unbalanced sum score are
higher, e.g., 37 nfvPPA patients per group assuming the
same treatment effect. The presented data are based on
the imputation calculation; however, a comparison of
raw data without the imputation method showed nearly
the same findings (Additional file 3: Table S3). For a
comparison, we set up sample size calculations for the
FTLD-CDR as well. Again, assuming a treatment effect
of 50% reduction in the measured increase in the FTLD-
CDR score, a cohort of nfvPPA twice the size with 58
patients per group (placebo and verum) is needed to
prove a treatment effect. Considering lvPPA patients
even raises the number to 180 patients per group, while
svPPA patients show comparable results with the bal-
anced sum score, i.e., 76 patients per group for a 50% re-
duction (Additional file 4: Table S4).
Discussion
The overall aim of this analysis was to provide a clinical
score that can be used as an outcome measure in clinical
trials. With the aim of covering a range of important
aspects of language to provide one score for all PPA
subtypes, we identified eight cognitive tests, merging
them into one overall sum score. The two variants of
Table 2 Sample size calculation based on the observed mean decline of the sum score within 1 year
Treatment effect All PPA nfvPPA svPPA lvPPA
Mean decline N per group Mean decline N per group Mean decline N per group Mean decline N per group
Balanced sum score
10% –4.35 690 –5.82 712 –3.4 1815 –3.48 709
20% –8.7 173 –11.63 178 –6.8 454 –6.97 178
30% –13.04 77 –17.45 80 –10.19 202 –10.45 79
40% –17.39 44 –23.26 45 –13.59 114 –13.94 45
50% –21.74 28 –29.08 29 –16.99 73 –17.42 29
60% –26.09 20 –34.9 20 –20.39 51 –20.9 20
70% –30.44 15 –40.71 15 –23.79 38 –24.39 15
80% –34.78 11 –46.53 12 –27.18 29 –27.87 12
90% –39.13 9 –52.34 9 –30.58 23 –31.36 9
100% –43.48 7 –58.16 8 –33.98 19 –34.84 8
Unbalanced sum score
10% –2.66 1110 –3.53 913 –2.14 1674 –2.32 963
20% –5.33 278 –7.06 229 –4.28 419 –4.64 241
30% –7.99 124 –10.59 102 –6.42 186 –6.96 107
40% –10.66 70 –14.12 58 –8.56 105 –9.28 61
50% –13.32 45 –17.65 37 –10.71 67 –11.61 39
60% –15.98 31 –21.17 26 –12.85 47 –13.93 27
70% –18.65 23 –24.7 19 –14.99 35 –16.25 20
80% –21.31 18 –28.23 15 –17.13 27 –18.57 16
90% –23.98 14 –31.76 12 –19.27 21 –20.89 12
100% –26.64 12 –35.29 10 –21.41 17 –23.21 10
Percent values indicate a reduction in cognitive decline, the required number of cases per group (N per group) corresponds to verum and placebo
The power was set to 80%, and the alpha error level to 5% for the use of a unpaired t test
nfvPPA (N = 27), svPPA (N = 16), lvPPA (N = 12)
lvPPA logopenic variant primary progressive aphasia, nfvPPA nonfluent variant primary progressive aphasia, svPPA semantic variant primary progressive aphasia
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this score, one comprising a simple summation of all
raw scores obtained, the second a balanced version pre-
cluding unbalanced weights for single scores, showed
overall high progressive decline between –9% and –13%
at 1 year, which is in line with the results of Hsieh et al.
[7], who reported an approximate 10% reduction in a
cognitive screening tool (Addenbrooke’s Cognitive
Examination-Revised) in PPA patients. We did not find
any meaningful differences in sum score decreases
between the PPA subgroups, preventing a differentiation
between the diagnostic groups. At baseline, the sum
scores and clinical rating scale FTLD-CDR showed rele-
vant correlations with r ≈ –0.6, suggesting a good overall
representation of cognitive status. A correlation between
sum score and volumetric changes showed slightly
higher relations for the balanced score version, including
both the left frontal lobe (r = 0.647) and the left putamen
(r = 0.593). Although it has to be noted here that the
quite high correlations seem to be reinforced by a strong
progressive decline in single patients, we also see evi-
dence that the cognitive decline measured by the sum
score reflects atrophy progression.
Regarding the decrease rates of the cognitive assess-
ments, we detected considerable variation between the
PPA subgroups, with nfvPPA descriptively showing
greater progression than svPPA and lvPPA. Up to 20%
absolute percentage reductions for single assessments
were revealed within 1 year.
Based on our cohort, we set up sample size calcula-
tions with the new scores to review applicability for
possible prospective clinical trials. Assuming a treatment
effect of 50% reduction in cognitive decline, 28 cases per
placebo and verum group would be needed, using the
balanced sum score, calculated for PPA as an entire
group. Using the unbalanced sum score generally in-
creases the cases needed, for example in the above-
mentioned example to 45 cases per group. A comparison
between the PPA groups shows similar numbers in
nfvPPA and lvPPA, whereas in svPPA higher case
numbers are needed. Higher variance values in the latter
group are likely to account for this difference. Sample
size estimations based on the FTLD-CDR revealed
higher case numbers. For example, again assuming a
treatment effect of 50% reduction in cognitive decline as
mentioned above, 93 patients per group are needed.
Compared with previous samples size calculations
which were based on volumetric brain changes as an
outcome measure [8, 9], comparable numbers were
found. Using a cognitive assessment as an outcome
measure shows a clear advantage, as it is easy to im-
plement and time saving in tabulation. Comparing the
two versions of the sum score, the balanced score
seems to be preferable since it shows higher correla-
tions with atrophy progression, clinical rating scales,
and fewer numbers in the sample size calculation.
Furthermore, it provides equal emphasis for the single
assessments.
Although this is the largest follow-up study on PPA
patients to our knowledge, a limitation of this study is
the still small and unbalanced sample size. Our cohort
showed considerable variation in disease progression at
baseline and a more uniform sample would clearly be
desirable. Additionally, it should be mentioned that the
sum score includes an assessment which had been devel-
oped for the German language (AAT written language)
and is based on normative data of German speaking
samples. A simple transfer of the sum score characteris-
tics into different languages must be taken with caution.
Conclusion
Our results show overall high decline in language-
specific neuropsychological tests within 1 year for all
PPA subtypes and progressive atrophy in frontal and
temporal regions. Based on our cohort, we combined
the most informative neuropsychological assessments
covering different aspects of language to a new sum
score, which showed high correlations with the frontal
atrophy rate. Subsequent sample size calculations
showed feasible numbers; therefore, we believe that we
now hold a practical tool for investigating PPA patients,
especially with a focus on nfvPPA patients at follow-up,
which can be used for clinical trials.
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